Showing results (51-60 of 365) with videos related to
Sort By:
Pageof 37
Health Services Research|January 1, 1975
Determinants of hospital utilization in the NetherlandsJ van der Gaag, F F Rutten, B M van PraagEuropean Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantationC A Uyl-de Groot, D J Richel, F F RuttenEuropean Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Economic evaluation alongside cancer trials: methodological and practical aspectsG J Bonsel, F F Rutten, C A Uyl-de GrootHealth Policy (Amsterdam, Netherlands)|October 28, 1999
Assessment of biotechnology drugs: what are the issues?J van Rijkom, H Leufkens, D Crommelin, et al.Pharmacoeconomics|May 27, 1999
The burden of illness of hypopituitary adults with growth hormone deficiencyL Hakkaart-van Roijen, A Beckers, A Stevenaert, et al.Nederlands Tijdschrift Voor Geneeskunde|April 13, 1991
[Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine]L L Martens, F F Rutten, J L Kuijpens, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Measurement and valuation of quality of life in economic appraisal of cancer treatmentC A Uyl-de Groot, F F Rutten, G J BonselPharmacoeconomics|June 6, 1996
Colony-stimulating factors and peripheral blood progenitor cell transplantation. Benefits and costsC A Uyl-de Groot, P C Huijgens, F F RuttenPharmacoeconomics|March 31, 2001
Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspectiveC Chevat, B M Peña, M J Al, et al.Current Opinion in Clinical Nutrition and Metabolic Care|October 24, 2002
Antioxidants and Alzheimer's disease: from bench to bedside (and back again)Bart P F Rutten, Harry W M Steinbusch, Hubert Korr, et al.Pageof 37